Pharm
Clevidipine
search
Clevidipine
, Cleviprex
See Also
Nicardipine
Dihydropyridine Calcium Channel Blocker
Indications
Hypertensive Emergency
Contraindications
Allergic Reaction
to Clevidipine or its components
Cross reactivity with soy and soybeans, egg and egg product allergies
Lipid Metabolism
defect
Severe
Aortic Stenosis
Exercise
caution in
Congestive Heart Failure
Pheochromocytoma
Hypertensive Emergency
management with
Alpha Adrenergic Receptor
Antagonist
with or without
Beta Blocker
Mechanism
Parenteral
Dihydropyridine Calcium Channel Blocker
Arterial
Smooth Muscle
dilation
Decreases
Peripheral Vascular Resistance
(
Afterload
reduction)
Minimal to no effect on
Preload
, cardiac conduction, or cardiac contractility
However
Calcium Channel Blocker
s may have negative inotropic effects
Pharmacokinetics
Onset: <2 minutes (systolic
Blood Pressure
response)
Half-Life
: 1 minute
Return to baseline
Blood Pressure
5-15 minutes after discontinuing infusion
Dosing
Start: 1-2 mg/hour IV infusion
Titrate: Double dose (as often as every 90 seconds, then every 5-10 min) until approaching target
Blood Pressure
Blood Pressure
drops 2-4 mmHg for every 1-2 mg/h
Target
Typical maintenance dose 4-6 mg/h
Half of maximal effect reached at 10 mg/h
Maximum
Typical maximum dose 16 mg/h
Absolute maximum dose 32 mg/h
Adverse Effects
Common
Nausea
or
Vomiting
Headache
Serious
Hypotension
Reflex
Tachycardia
Congestive Heart Failure
Exacerbation
Rebound
Hypertension
Prevent by transitioning onto other
Antihypertensive
s before discontinuing Clevidipine
Safety
Pregnancy Category C
Unknown Safety in Pregnancy
References
(2022) Presc Lett, Resource #381108, Comparison of
Calcium Channel Blocker
s
Kristensen and LoVecchio (2020) Crit Dec Emerg Med 34(9): 28
Tarascon Pharmacopeia, accessed 2/11/2021
Type your search phrase here